Phase III Trial of Blinatumomab vs Chemotherapy as Post-Reinduction Therapy for Children and Young Adults With Relapsed B-ALL

December 7-10, 2019; Orlando, Florida
In children and young adults with intermediate- and high-risk first relapse of B-ALL, blinatumomab improved outcomes vs chemotherapy when administered as post-reinduction consolidation therapy prior to transplant.
Format: Microsoft PowerPoint (.ppt)
File Size: 215 KB
Released: December 20, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Downloadable slideset of FcRn pathway inhibition in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of BTK inhibitors in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of an expert’s overview of emerging therapies for patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of complement inhibition in patients with ITP, from Clinical Care Options (CCO)

person default Catherine M. Broome, MD Released: July 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue